Aquestive (AQST) awards Abigail Jenkins 50,500 stock options at $3.99

Rhea-AI Filing Summary

Aquestive Therapeutics director Abigail L. Jenkins received an equity award of non-qualified stock options for 50,500 shares of common stock. The options have an exercise price of $3.99 per share, expire on June 10, 2036, and represent her direct holdings of this option grant.

All 50,500 underlying shares vest on June 10, 2027, provided she remains in continuous service with the company through that date. This is a compensation-related grant, not an open-market purchase or sale, so it mainly updates her potential future ownership rather than reflecting a trading decision.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Jenkins Abigail L.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Non-Qualified Stock Option (right to buy)	50,500	$0.00	--

Holdings After Transaction: Non-Qualified Stock Option (right to buy) — 50,500 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Option grant size: 50,500 options Exercise price: $3.99 per share Vesting date: June 10, 2027 +3 more

6 metrics

Option grant size 50,500 options Non-qualified stock option award to Abigail L. Jenkins

Exercise price $3.99 per share Strike price for the non-qualified stock options

Vesting date June 10, 2027 100% of underlying shares vest on this date

Expiration date June 10, 2036 Date the options expire if not exercised

Underlying shares 50,500 shares Common stock underlying the option grant

Post-transaction option holdings 50,500 options Total options held for this award after the transaction

Key Terms

Non-Qualified Stock Option (right to buy), vest, exercise price, expiration date, +1 more

5 terms

Non-Qualified Stock Option (right to buy) financial

"security_title: Non-Qualified Stock Option (right to buy)"

vest financial

"100% of the underlying shares vest June 10, 2027"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

exercise price financial

"conversion_or_exercise_price: 3.9900"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-10T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

underlying shares financial

"100% of the underlying shares vest June 10, 2027"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/12/2026 - 11:43 AM Accepted by SEC EDGAR 06/12/2026 - 11:42 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jenkins Abigail L.

(Last) (First) (Middle)

C/O AQUESTIVE THERAPEUTICS, INC.

30 TECHNOLOGY DRIVE

(Street)

WARREN NEW JERSEY 07059

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Aquestive Therapeutics, Inc. [ AQST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualified Stock Option (right to buy)	$3.99	06/10/2026		A			50,500	06/10/2027(1)	06/10/2036	Common Stock	50,500	$0	50,500	D

Explanation of Responses:

1. The shares underlying the options vest as follows: 100% of the underlying shares vest June 10, 2027, subject to Ms. Jenkins' continuous service with the Issuer from the grant date through the applicable vesting date.

Remarks:

	/s/ Thomas Zalewski, as Attorney-In-Fact	06/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Abigail L. Jenkins report in this Aquestive Therapeutics (AQST) Form 4?

Abigail L. Jenkins reported receiving a grant of 50,500 non-qualified stock options. These options give her the right to buy Aquestive Therapeutics common stock at $3.99 per share, subject to vesting and an expiration date in 2036.

How many Aquestive Therapeutics (AQST) options were granted to Abigail Jenkins and at what price?

She was granted 50,500 non-qualified stock options with an exercise price of $3.99 per share. This price is the amount she would pay per share if she chooses to exercise the options after they vest.

When do Abigail Jenkins' Aquestive Therapeutics (AQST) stock options vest?

All 50,500 underlying shares vest on June 10, 2027. Vesting is contingent on Ms. Jenkins maintaining continuous service with Aquestive Therapeutics from the grant date through that vesting date, according to the disclosed footnote.

When do Abigail Jenkins' Aquestive Therapeutics (AQST) options expire?

The non-qualified stock options expire on June 10, 2036. If the options are not exercised by that expiration date, the right to buy 50,500 shares at $3.99 per share will lapse and become worthless.

Is Abigail Jenkins buying or selling Aquestive Therapeutics (AQST) stock in this Form 4?

She is not buying or selling shares in the market; she is receiving an option grant. The Form 4 reports a compensation-related award of 50,500 non-qualified stock options, rather than an open-market purchase or sale of common stock.

How many Aquestive Therapeutics (AQST) options does Abigail Jenkins hold after this transaction?

After this grant, she holds 50,500 non-qualified stock options as reported for this award. The filing shows this total for the granted option position, with no additional derivative holdings listed in the derivative summary section.